Neoadjuvant Toripalimab Plus Platinum-based Doublet for Stage III Non-small Cell Lung Cancer

Summary

This is an open-label, single-arm, phase II, multi-center clinical trial. Thirty patients will be enrolled in this trial to investigate the pathological complete response rate defined as the absence of residual tumor in lung and lymph nodes treated by chemo-immunotherapy.

Timeline

Start

2019-08-01

Primary completion

2026-07-30

Completion

2026-07-30

Publications

• Zhao ZR, Yan WP, Yu XY, Zhang JB, Fang YF, Ma K, Luo QQ, Long H, Chen KN, Jiang L. Adjuvant immunotherapy does not improve survival in non-small cell lung cancer with major/complete pathologic response after induction immunotherapy. J Thorac Cardiovasc Surg. 2025 Jun;169(6):1576-1584.e3. doi: 10.1016/j.jtcvs.2024.11.028. Epub 2024 Nov 29.
• Zhao ZR, Yang CP, Chen S, Yu H, Lin YB, Lin YB, Qi H, Jin JT, Lian SS, Wang YZ, You JQ, Zhai WY, Long H. Phase 2 trial of neoadjuvant toripalimab with chemotherapy for resectable stage III non-small-cell lung cancer. Oncoimmunology. 2021 Oct 25;10(1):1996000. doi: 10.1080/2162402X.2021.1996000. eCollection 2021.

Drugs

Indications